共 50 条
Luteolin attenuated cisplatin-induced cardiac dysfunction and oxidative stress via modulation of Keap1/Nrf2 signaling pathway
被引:13
|作者:
Qi, Yajun
[1
,2
]
Fu, Shuang
[3
,4
]
Pei, Donggen
[5
]
Fang, Qilu
[1
,2
]
Xin, Wenxiu
[1
,2
]
Yuan, Xiaohong
[3
,4
]
Cao, Yingying
[1
,2
]
Shu, Qi
[1
,2
]
Mi, Xiufang
[1
,2
]
Luo, Fang
[1
,2
]
机构:
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pharm, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Pharm, Hangzhou, Zhejiang, Peoples R China
[3] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China
[4] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China
[5] Nanjing Med Univ, Childrens Hosp, Dept Pharm, Nanjing, Peoples R China
关键词:
Luteolin;
cisplatin;
oxidative stress;
Keap1;
Nrf2;
INDUCED CARDIOTOXICITY;
NRF2;
PROGRESSION;
MECHANISMS;
INJURY;
AMPK;
D O I:
10.1080/10715762.2022.2067042
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Cardiovascular complications are a well-documented limitation of cancer chemotherapy. Cisplatin-induced cardiotoxicity threatens the health and life of patients, and limits the application of cisplatin. Oxidative stress is the main mechanism underlying cisplatin-induced cardiac toxicity. Luteolin (Lut) has been reported to possess cardioprotective properties by activating nuclear factor-E2-related factor 2 (Nrf2) -mediated antioxidant response. However, the effect of Lut on cisplatin-induced cardiac damage remains unclear. In this study, we revealed that Lut exerted a protective effect against cisplatin-induced cardiac dysfunction and injury in vivo. In HL-1 cells, Lut was observed to dramatically reduce cisplatin-induced apoptosis and oxidative stress by modulating the Kelch-like epichlorohydrin-associated protein 1 (Keap1)/Nrf2 pathway. Altogether, these findings suggested that Lut showed promise in attenuating cisplatin-induced cardiac injury and might be considered a protective drug candidate for chemotherapy-associated cardiovascular complications.
引用
收藏
页码:209 / 221
页数:13
相关论文